Eli Lilly Partners with OpenAI

In an effort to create novel therapies for diseases resistant to drugs, Eli Lilly has partnered with OpenAI, joining an increasing number of pharmaceutical corporations in this regard.

The partnership will make use of OpenAI’s generative AI to develop fresh approaches to treating microbial illnesses. Lilly did not disclose the financial parameters of the agreement or the precise circumstances under which OpenAI’s technology will be utilised.

By working with OpenAI, Lilly is furthering its dedication to combating antimicrobial resistance. The multinational pharmaceutical company has already donated $100 million to the AMR Action Fund, a global effort to fund antibiotic research in order to combat the rising threat of antimicrobial resistance.

But using AI might make it possible for scientists to find new antibiotics faster and more precisely than they did in the past using conventional approaches.

Lilly’s digital officer Diogo Rau stated: “Generative AI opens a new opportunity to accelerate the discovery of novel antimicrobials and the development of custom, purpose-built technologies in the battle against drug-resistant pathogens.”